URGN Q2 2025 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena

URGNUroGen Pharma Ltd.

$927M

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$24M+10.8% YoY

Gross Profit

$21M85.3% margin

Operating Income

-$41M-171.2% margin

Net Income

-$50M-206.2% margin

EPS (Diluted)

$-1.05

QoQ Revenue Growth

+19.6%

Cash Flow

Operating Cash Flow

-$40M

Free Cash Flow

-$40M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$209M

Total Liabilities

$302M

Stockholders' Equity

-$93M

Cash & Equivalents

$93M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$24M	$22M	+10.8%
Gross Profit	$21M	$20M	+5.3%
Operating Income	-$41M	-$26M	-60.4%
Net Income	-$50M	-$33M	-49.5%

Revenue Segments

Jelmyto

$24M100%